London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
L, the "strengthened board" implementation has only just happened with new COO coming in, yet Inaphaea & beyond blood collabs were signed some time ago. The new COO can exert their skills now to enhance these, but hos impact would not have been felt before his arrival.?
Outlook
The impact of the Company's strengthened Board is already being felt through the implementation of new marketing activities, collaborations such as with Inaphaea and Beyond Blood and through the proposed expansion of its consulting business into the field of biostatistics. The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering.
But you haven't bought PYC at all
You've posted almost for a year on HARL and before that hadn't posted posted for a few yews
Instead you've posted twice on PYC both times with a negative slant
God help us if we are relying on jam tomorrow Valirx to get us out of the mire.Made a huge mistake investing in PYC,still lessons learned
Https://www.valirx.com/news/valirx-qa-session-dr-suzanne-dilly-and-dr-kevin-cox
https://www.brrmedia.co.uk/broadcasts-embed/65142ddf01d979c8a2ec78b2/valirx-qa-session/?popup=true#
VAL201 looks highly likely soon according to Suzy. That will be huge for both companies.
No they weren't Laura. Back in May they stated an approx income of 660k. It came in at 605k. That's significantly lower than the initial estimate.
Exactly Ackers
The numbers for year ended June were already stated back in May ? Nearly 5mths ago, since July the momentum has increased with 4 contracts,Merck have come back and there is over £1mln+ pipeline for current year alone
A reminder of where the company is is 1.8p
After the last few years big noises about record revenues and strong pipelines neither the BOD or the posters on here have any credibility left.
"This was facilitated through the implementation of a formal CRM process to manage and track opportunities".
I had to maintain a CRM system in my first job after leaving university, that was 35 years ago. I guess if you have limited enquiries and even less actual customers it's not needed. A reminder of where the company actually is. Out of small acorns etc etc.........
Was this the imminent incoming news you were on about several weeks ago Laura?
Is that record losses then?
Not interested in past .
Positive outlook for current year,more contracts.
Pleased and comfortable with my investment.
Acker
Nothing has changed, same old rhetoric, same old Results, same old PYC.
I predict though that 2026 will be a year to celebrate when we’ve had 25 years of this sad story…..
Clarets
Don't forget AFTER these results Merck came back on board and spend €500k+ annually ( main reason for the slip to £609k rev) and from today's RNS
For the first time ever, the Company has felt in a position to quantify the value of its pipeline of potential new contracts that could start in the current financial year which remains at over £1m despite four opportunities having been converted into signed projects during August. This was facilitated through the implementation of a formal CRM process to manage and track opportunities.
We already knew what the financials were going to show following one of the previous rns's. There is more in the outlook statement than ever before. What we need in the next month is a couple of new/renewed contracts to show that the management can walk the walk.
A different way to the layout presenting the annual report?
"exploring possible augmentation of the tool " ?
"The personalised medicine and digital health space continues to generate significant interest from both investors and healthcare systems. Many start-ups in this area focus on the use of genetic markers or the pattern-recognition capabilities of artificial intelligence applications. However, we believe that there is a significant opportunity in the analysis of existing clinical data to identify better ways to treat patient using existing drugs and procedures"
"The Company is focused on the creation of long-term value for its shareholders. " my question is how long!.......
The Company is looking forward to a successful financial year 2024 during which it aims to achieve a new best ever level of total income, generated from its current core business and emerging biostatistics consulting offering.
I may be wrong, but there are only "posters" to be presented at this AACR?
There are approx 176 in session A
There are approx 179 in Session B
There are approx 175 in session C
There are approx 25 in the late breaking session A
There are approx 26 in late breaking session B
There are approx 22 in late breaking session C
Ankyra are Boston based, and event being held in Boston.
Bicycle, Merck group and ICR are all there presenting posters.
Along with a plethora of companies from around the world.
Https://www.aacr.org/wp-content/uploads/2023/09/MTCT2023_postersC_titles-2.pdf
Listed here A141. Looks like David Hodson is running it?
309k buy near the bell moved it from red to flat, it was well above the offer.
Someone decided to dump 600k this morning at well below the bid.
Hi msuk
How do this....can you tell they are doing it
Thanks
L
Mm's were keeping it down ....i watched PA from start to finish
I will do some digging on this later this evening . 3 people going let's hope they are flying cattle class ,& staying in a very cheap hotel!
Fantastic Trench
I am trying to purchase some more at 2.1p but there is none available